Cochrane · systematic review · CD007949
Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children
Chauhan, BF, Chartrand, C, Ni Chroinin, M, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
AirwaysAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 14.3%Moderate 11 · 78.6%High 1 · 7.1%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Comparison
Population: children with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with exacerbations requiring systemic steroids | RR 0.95 [0.7, 1.28] | 12 studies · 1669 participants | Moderate Downgraded: imprecision |
Number of participants with exacerbations requiring hospitalisation | RR 1.74 [0.9, 3.36] | 6 studies · 1292 participants | Moderate Downgraded: imprecision |
Serious adverse events | RR 1.17 [0.75, 1.85] | 16 studies · 4022 participants | Moderate Downgraded: imprecision |
Total number of withdrawals | RR 0.8 [0.67, 0.94] | 23 studies · 4374 participants | Low Downgraded: imprecision |
Change in FEV1 (L) at endpoint | no estimate extracted | 9 studies · 1942 participants | Low Downgraded: imprecision |
Change in morning PEF (L/min) at endpoint | no estimate extracted | 16 studies · 3934 participants | Moderate Downgraded: imprecision |
Total number of adverse events | RR 1.04 [0.98, 1.1] | 15 studies · 3284 participants | Moderate Downgraded: imprecision |
Comparison
Population: children with chronic asthma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Number of participants with exacerbations requiring systemic steroids | RR 1.69 [0.85, 3.32] | 3 studies · 581 participants | Moderate Downgraded: imprecision |
Number of participants with exacerbations requiring hospitalisation | RR 1.9 [0.65, 5.54] | 4 studies · 1008 participants | Moderate Downgraded: imprecision |
Serious adverse events | RR 1.54 [0.81, 2.94] | 7 studies · 1343 participants | Moderate Downgraded: imprecision |
Total number of withdrawals | RR 0.96 [0.67, 1.37] | 7 studies · 1491 participants | Moderate Downgraded: imprecision |
Change in FEV1 (L) at endpoint | no estimate extracted | 2 studies · 526 participants | Moderate Downgraded: imprecision |
Change in morning PEF (L/min) at endpoint | no estimate extracted | 5 studies · 1283 participants | Moderate Downgraded: imprecision |
Total number of adverse events | RR 1.01 [0.92, 1.1] | 6 studies · 1254 participants | High |